MiMedx Group, Inc. (NASDAQ:MDXG) Receives $12.00 Consensus Price Target from Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been assigned a consensus rating of “Buy” from the four brokerages that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $12.00.

Several equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. grew its stake in shares of MiMedx Group by 2.2% in the fourth quarter. Invesco Ltd. now owns 56,565 shares of the company’s stock worth $544,000 after purchasing an additional 1,226 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in MiMedx Group by 1.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company’s stock valued at $1,082,000 after buying an additional 1,822 shares in the last quarter. Disciplined Growth Investors Inc. MN boosted its stake in MiMedx Group by 0.8% during the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock valued at $2,100,000 after buying an additional 2,737 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after buying an additional 2,837 shares in the last quarter. Finally, IMG Wealth Management Inc. bought a new position in MiMedx Group during the fourth quarter valued at about $28,000. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $8.09 on Thursday. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The business’s fifty day moving average price is $8.66 and its two-hundred day moving average price is $7.75. The firm has a market capitalization of $1.19 billion, a PE ratio of 14.71 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. On average, research analysts expect that MiMedx Group will post 0.3 EPS for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.